Brilacidin

Drug Profile

Brilacidin

Alternative Names: Brilacidin tetrahydrochloride; Brilacidin-Ocular; Brilacidin-OM; Brilacidin-Otic; Defensin-mimetic - Cellceutix; HDP-mimic - Cellceutix; Host defense protein-mimic - Cellceutix; PMX-30063

Latest Information Update: 19 Mar 2017

Price : $50

At a glance

  • Originator PolyMedix
  • Developer Cellceutix
  • Class Antibacterials; Peptidomimetics; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Stomatitis
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Skin and soft tissue infections; Stomatitis; Ulcerative colitis
  • Preclinical Acne; Atopic dermatitis; Diabetic foot ulcer; Hidradenitis suppurativa; Intestinal infections; Ophthalmic infections; Otitis; Wounds

Most Recent Events

  • 08 Mar 2017 Interim efficacy, pharmacokinetics and adverse events data from a phase II proof-of-concept trial in Ulcerative colitis released by Cellceutix
  • 17 Jan 2017 Cellceutix completes enrolment in the second cohort in its phase II trial for Ulcerative colitis in USA (Rectal)
  • 07 Dec 2016 Interim adverse events data from a phase II proof-of-concept trial in Ulcerative colitis released by Cellceutix
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top